Alan Thomas, MD
Sleep Medicine · Birmingham, ALNPI 1528066313
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,942 of the $13,098 with a category attached, or 83.5%. 50 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. Reporting peaked in 2021 at $3,190 and has fallen 58.2% since, to $1,333 in 2025.
Across 595 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Electromed, Inc.$809
- Grifols USA, LLC$687
- Inspire Medical Systems, Inc.$571
- plus $4K from 44 others
Across 159 payments — averaging $2205.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$185K
- Jazz Pharmaceuticals Inc.$88K
- GSK$40K
- AstraZeneca$20K
- Sanofi US Services Inc.$18K
What the payments were for
- Speaking & faculty fees$2,10016%
- Travel & lodging$210%
- Food & beverage$10,94284%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI AEROSPHERE$1,578
- BREZTRI$650
- Inspire Upper Airway Stimulation System$459
- TRELEGY ELLIPTA$111
- NUCALA$105
How this compares
$13,098 in reported general payments places this provider in the 65th percentile of 28 sleep medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $172,330 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $146,192 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $9,791 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,464 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,428 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,652 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,724 |
| Roflumilast | 43 | $2,549 |
| Ventolin HfaAlbuterol Sulfate | 15 | $827 |
| Montelukast Sodium | 15 | $93 |
| Prednisone | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat | $1,204 | $178,75827 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,396 | $155,983222 claims |
| AstraZenecaBreztri Aerosphere | $3,303 | $7,46412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 28 sleep medicine providers in Alabama.
Other sleep medicine in Birmingham
- Erin OzgunBirmingham$16K
- Robert DoekelBirmingham$6K
- William AdamsBirmingham$3K
- Melissa JordanBirmingham$2K
- Weddington KelleyBirmingham$940
- Syed NabiBirmingham$457
- Stuart PadoveBirmingham$15
- James RoyHuntsville$823K
- Michael LedetDaphne$795K
- Gordon WarnerCullman$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.